share_log

Senti Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Rajangam Kanya

SEC announcement ·  Feb 3 06:33
Summary by Futu AI
Senti Biosciences, Inc. (SNTI.US) reported that its Chief Medical & Development Officer, Rajangam Kanya, was granted 101,000 shares of common stock on February 1, 2024. The transaction, which was completed on the same day, was a grant with no cost associated with the acquisition. Following this transaction, Kanya directly holds a total of 101,000 shares in the company. The grant is part of the company's compensation strategy for its executives and is indicative of the company's commitment to aligning the interests of its leadership with those of its shareholders.
Senti Biosciences, Inc. (SNTI.US) reported that its Chief Medical & Development Officer, Rajangam Kanya, was granted 101,000 shares of common stock on February 1, 2024. The transaction, which was completed on the same day, was a grant with no cost associated with the acquisition. Following this transaction, Kanya directly holds a total of 101,000 shares in the company. The grant is part of the company's compensation strategy for its executives and is indicative of the company's commitment to aligning the interests of its leadership with those of its shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.